公开(公告)号：AU2009234106A1

公开(公告)日：2009-10-15

申请号：AU2009234106

申请日：2009-03-04

Applicant: SINGULEX INC

Inventor： GOIX PHILIPPE J ,  HELD DOUGLAS ,  PUSKAS ROBERT ,  TODD JOHN ,  AGEE SARA ,  LIVINGSTON RICHARD A

IPC: A61B5/02 ,  C12Q1/28 ,  C12Q1/68 ,  G01N33/00 ,  G01N33/53 ,  G01N33/68 ,  G01N33/92

Abstract: The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnI) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.

公开(公告)号：GB2458025A

公开(公告)日：2009-09-09

申请号：GB0903848

申请日：2009-03-05

Applicant: SINGULEX INC

Inventor： GOIX PHILIPPE J ,  PUSKAS ROBERT ,  TODD JOHN ,  LIVINGSTON RICHARD A ,  HELD DOUGLAS ,  AGEE SARA

IPC: G01N33/58 ,  G01N33/68

Abstract: A method for detecting and monitoring a condition in a subject using a single molecule detector is disclosed comprising detecting a first marker in a first sample from the subject, wherein the first marker comprises a biomarker such as Cardiac Troponin-I (cTnI), and wherein the limit of detection of the first marker is less than 20 pg/ml, and further comprising the detection of a second marker as a further indication of the condition to be detected. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker. Also claimed are similar methods involving the detection of Vascular Endothelial Growth Factor (VEGF), pro B-type Natriuretic Peptide (proBNP), TREM-1, Interleukin 1 Alpha (IL-1 a ), IL- 1 b , IL-4, IL-6, IL-8, IL-10, Interferon gamma (IFN- q ), Tumour Necrosis Factor alpha (TNF- a ), Glucagon-like peptide-1 (GLP-1), Leukotriene E4 (LTE4), Transforming Growth Factor Beta (TGF- b ), Akt1, A b -40, A b -42, and Fas ligand (FasL). The markers may be detected using fluorescent labels.

公开(公告)号：CA3086149A1

公开(公告)日：2007-10-11

申请号：CA3086149

申请日：2007-04-04

Applicant: SINGULEX INC

Inventor： GOIX PHILIPPE ,  PUSKAS ROBERT ,  TODD JOHN ,  LIVINGSTON RICHARD ,  HELD DOUGLAS ,  WU ALAN H

IPC: G01N33/48 ,  C12Q1/32 ,  C12Q1/48 ,  G01N15/10 ,  G01N33/53

Abstract: ABSTRACT Methods for sensitive detection of cardiac troponin are described for diagnosis, prognosis, and determination of treatment in conditions that involve release of cardiac troponin. A method for determining cardiovascular health of an individual comprises measuring serum or plasma concentration of Cardiac Troponin I (cTnI) and/or Cardiac Troponin T (cTnT), determined by an assay with a cTnI or cTnT detection limit of less than 10 pg/mL. Concentrations are compared to a predetermined threshold representing the 99th percentile of cTnI or cTnT with a corresponding coefficient variation of 10% or less in normal individuals. Cardiac damage or disease is determined when sample concentration is above threshold. A method of evaluating an individual for a previous cardiac event comprises detecting a concentration of cTnI in a sample and determining a previous cardiac event when cTnI level is greater than 7 pg/mL. Date Recue/Date Received 2020-07-08

公开(公告)号：CA2648385A1

公开(公告)日：2007-10-11

申请号：CA2648385

申请日：2007-04-04

Applicant: SINGULEX INC

Inventor： TODD JOHN ,  PUSKAS ROBERT ,  GOIX PHILIPPE ,  LIVINGSTON RICHARD ,  HELD DOUGLAS

IPC: G01N33/53

Abstract: The invention provides methods for diagnosing, predicting or prognosing acute myocardial infarction in an individual based on the sensitive detection of cardiac troponin.

公开(公告)号：AU2007233320A1

公开(公告)日：2007-10-11

申请号：AU2007233320

申请日：2007-04-04

Applicant: SINGULEX INC

Inventor： TODD JOHN ,  PUSKAS ROBERT ,  HELD DOUGLAS ,  GOIX PHILIPPE ,  LIVINGSTON RICHARD

IPC: G01N33/53

Abstract: The invention provides methods for diagnosing, predicting or prognosing acute myocardial infarction in an individual based on the sensitive detection of cardiac troponin.